Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect
Phase of Trial: Phase II
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Pegloticase (Primary)
- Indications Gout
- Focus Therapeutic Use
- Acronyms TRIPLE
- 14 Sep 2017 Additional pharmacokinetic (PK) assessments of pegloticase by measuring Area Under the Curve in a subset of subjects receiving loading doses of 12 and 16 mg added.
- 14 Sep 2017 Planned number of patients changed from 53 to 87.
- 14 Sep 2017 Planned End Date changed from 1 Jun 2018 to 1 Apr 2019.